Coherus Oncology

Q2 FY2026 EarningsQ2 FY26 results significantly missed consensus on the top line, with total revenue of $14.3M vs. $20.4M expected (-30.1% variance). Despite a 37% YoY increase in LOQTORZI® sales to $13.6M, the company remains deeply in the red with a GAAP net loss of $33.3M. However, aggressive cost-cutting in R&D and SG&A (both down ~19% YoY) allowed GAAP EPS of -$0.22 to slightly beat the -$0.20 consensus mean (but missed the -$0.115 normalized expectation). The cash position remains a concern, dropping to $105.3M from $172.1M at year-end, though key clinical readouts for the oncology pipeline are expected in 2H 2026.